Scale Business and Technology to Impact on Disease Research by with Lossless and...
Scale Business and Technology to Impact on Disease Research by with Lossless and Efficient Data Analysis
Aren’t we expecting from disease research that all available data is being used? Yes! Yet one of the biggest hurdles is the data variety when to studying underlying mechanisms or prioritizing targets for novel treatments. Ultimate...
Aren’t we expecting from disease research that all available data is being used? Yes! Yet one of the biggest hurdles is the data variety when to studying underlying mechanisms or prioritizing targets for novel treatments. Ultimately stalling projects and resulting in low output and quality. knowing01 GmbH is a deep tech software company founded in 2020 in Munich, Germany that gives Life Scientists full control of all their research data. Dr. Nikola Müller (founder and CEO) has spearheaded the project since 2014, when the idea budded during her academic research at Helmholtz Munich. The knowing01 solution is a software-as-a-service (SaaS) suite that allows the user to connect and explore omics data no matter their biodata type. Our innovative knowledge-graph based translation approach empowers scientists to run analyses across data types and compare different sets in their biological context. We additionally offer on client premise, licensed software. Our next challenging milestone is to scale a) by innovating the business and b) by having a critical assessment of the technology. We aim to exploit our niche market position. We are specifically aiming to be attractive to key partners that offer our together with their own services. We need scale our infrastructure and database-related technologies alongside with the business. Only both will allow us to future-proof our business paving the way for a sustainable business. Dr. Nikola Müller will profit from being part of the Women Leadership Program by sharpening negotiation skills, learning how to improve public visibility and finally, getting into potent female-friendly investor networks. Compared to classical IT, biotech or digital health companies, our offering opens a yet unexplored niche, which is why we will enormously profit from the Women TechEU grant. The non-dilutive funding will be critical of us being able to support the scale-developments to be able to move our business forward.ver más
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.